Abstract: The present invention discloses a flue gas low-temperature adsorption denitrification method, including: pressurizing a flue gas that has been subjected to dust removal and desulfurization, precooling the pressurized flue gas, cooling the precooled flue gas to a temperature lower than room temperature by a flue gas cooling system, flowing the flue gas at the temperature lower than room temperature into a low-temperature denitrification system, performing physical adsorption denitrification in the low-temperature denitrification system, precooling the flue gas that has been subjected to dust removal and desulfurization with the denitrificated flue gas, and flowing the heat-absorbed clean flue gas into a chimney to be discharged.

Abstract: A mopping module and a cleaning head. The mopping module includes a water tank, a mopping cloth, and a water volume control mechanism. A water tank hole is provided at a bottom portion of the water tank; the water tank hole communicates with the interior of the water tank; the mopping cloth is provided outside the bottom portion of the water tank; the water volume control mechanism comprises a knob and a water control tray; and by controlling the cooperation between the water control tray and the water tank hole via the knob, the amount of water flowing from the water tank to the mopping cloth through the water tank hole is adjusted.

Abstract: IFN-alpha mutants are obtained by substituting Cys for Tyr at position 85 or 86 in existing IFN-alpha. Their polyethylene glycol derivatives with high in vitro antiviral activity and prolonged in vivo half-life are also provided, wherein a polyethylene glycol moiety is covalently bound to the free Cys residue of an IFN-alpha mutant. The preparation methods of PEG derivatives of IFN-alpha mutants and medical compositions comprising the derivatives are also provided. The test results showed that the IFN-alpha mutants of the present invention are ready to prepare and have high activity; their polyethylene glycol derivatives have extended lifetime in the body and low clearance rate.

Abstract: IFN-alpha mutants are obtained by substituting Cys for Tyr at position 85 or 86 in existing IFN-alpha. Their polyethylene glycol derivatives with high in vitro antiviral activity and prolonged in vivo half-life are also provided, wherein a polyethylene glycol moiety is covalently bound to the free Cys residue of an IFN-alpha mutant. The preparation methods of PEG derivatives of IFN-alpha mutants and medical compositions comprising the derivatives are also provided. The test results showed that the IFN-alpha mutants of the present invention are ready to prepare and have high activity; their polyethylene glycol derivatives have extended lifetime in the body and low clearance rate.

Abstract: IFN-alpha mutants are obtained by substituting Cys for Tyr at position 85 or 86 in existing IFN-alpha. Their polyethylene glycol derivatives with high in vitro antiviral activity and prolonged in vivo half-life are also provided, wherein a polyethylene glycol moiety is covalently bound to the free Cys residue of an IFN-alpha mutant. The preparation methods of PEG derivatives of IFN-alpha mutants and medical compositions comprising the derivatives are also provided. The test results showed that the IFN-alpha mutants of the present invention are ready to prepare and have high activity; their polyethylene glycol derivatives have extended lifetime in the body and low clearance rate.

Abstract: IFN-alpha mutants are obtained by substituting Cys for Tyr at position 85 or 86 in existing IFN-alpha. Their polyethylene glycol derivatives with high in vitro antiviral activity and prolonged in vivo half-life are also provided, wherein a polyethylene glycol moiety is covalently bound to the free Cys residue of an IFN-alpha mutant. The preparation methods of PEG derivatives of IFN-alpha mutants and medical compositions comprising the derivatives are also provided. The test results showed that the IFN-alpha mutants of the present invention are ready to prepare and have high activity; their polyethylene glycol derivatives have extended lifetime in the body and low clearance rate.